In:
Drug Development Research, Wiley, Vol. 68, No. 4 ( 2007-06), p. 145-146
Kurzfassung:
The pharmaceutical industry, like so many industries today, is in a state of flux. Most of my graduate school colleagues, after completing their studies twenty‐odd years ago, joined large pharmaceutical companies with plans to stay with those organizations for their entire career. It was the best, if not the only, option for conducting cutting‐edge pharmaceutical discovery and development research during those years. Research and development programs in those corporations were very large and very well funded. Currently, the landscape is radically different. Much innovative research is being conducted in very small research and development operations, some with only a few workers, and some in larger organizations that qualify as mid‐size, specialty pharmaceutical companies. These larger organizations are still far from the scope and size of traditional, large organizations. Drug Dev Res 68:145–146, 2007. © 2007 Wiley‐Liss, Inc.
Materialart:
Online-Ressource
ISSN:
0272-4391
,
1098-2299
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2007
ZDB Id:
1500191-X
SSG:
15,3
Bookmarklink